Home » Healthcare » Pharmaceuticals » Cancer Biomarkers Market

Cancer Biomarkers Market By Product (Instruments, Consumables, Antibodies, Kits & Reagents, Probes); By Profiling Technologies (Omics Technologies \[Proteomics, Genomics], Imaging Technologies, Bioinformatics, Others); By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others); By Application (Pharmaceutical and Biotechnology Companies, Diagnostics, Drug Discovery & Development, Prognostics, Risk Assessment, Others); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Cancer Biomarkers Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-07-13
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Cancer Biomarkers Market

Summary
Table Of Content
Request Sample

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Cancer Biomarkers Market Size 2024	USD 24,567.0 Million
Cancer Biomarkers Market, CAGR	8.83%
Cancer Biomarkers Market Size 2032	USD 48,248.0 Million

Market Overview

The Cancer Biomarkers market size was valued at USD 14,646.2 million in 2018, increased to USD 24,567.0 million in 2024, and is anticipated to reach USD 48,248.0 million by 2032, at a CAGR of 8.83% during the forecast period.

The Cancer Biomarkers market is dominated by major players such as Qiagen N.V., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., and Sino Biological Inc. These companies maintain their competitive edge through advanced biomarker discovery platforms, strategic collaborations, and expansion of companion diagnostic offerings. North America leads the global market, accounting for 31.7% of total revenue in 2024, driven by robust R&D infrastructure, early adoption of precision medicine, and strong presence of key industry players. Europe follows closely, supported by favorable healthcare policies and increasing genomic research, while Asia Pacific emerges as the fastest-growing region due to rising cancer incidence and expanding access to diagnostics.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Insights

The Cancer Biomarkers market was valued at USD 14,646.2 million in 2018, reached USD 24,567.0 million in 2024, and is projected to hit USD 48,248.0 million by 2032, growing at a CAGR of 8.83% during the forecast period.
Market growth is primarily driven by the rising global prevalence of cancer, increasing demand for early detection, and advancements in genomics and proteomics technologies.
Omics technologies, especially genomics, dominate the profiling technologies segment, while consumables, particularly kits and reagents, account for the largest share by product.
The market is highly competitive, with key players including Roche, Qiagen, Thermo Fisher Scientific, and Illumina, investing in R&D, strategic alliances, and next-generation sequencing platforms.
North America led the market in 2024 with 31.7% share, followed by Europe (26.5%) and Asia Pacific (24.3%), with APAC expected to grow the fastest due to expanding healthcare infrastructure and high cancer burden.

Market Segmentation Analysis:

By Product

In the Cancer Biomarkers market, the consumables segment dominates, accounting for the largest market share in 2024. Within consumables, kits and reagents hold a significant portion due to their widespread application in diagnostic testing and cancer screening procedures. The increasing demand for high-throughput testing and advancements in biomarker-based assays have propelled growth in this segment. Additionally, the recurring need for consumables in laboratory workflows supports sustained revenue. The rising adoption of precision medicine and companion diagnostics in oncology further drives the demand for reliable, fast, and standardized consumable products.

For instance, Thermo Fisher Scientific’s TaqPath™ COVID-19, Flu A/B, and RSV Combo Kit was able to process up to 6,000 samples per day using its 7500 Fast Dx Real-Time PCR instrument, showcasing the scalability and efficiency of its consumables in high-throughput diagnostic settings.

By Profiling Technologies

Omics technologies emerged as the leading segment in 2024, with genomics accounting for the highest share among the sub-categories. This dominance is driven by the growing use of genomic biomarkers in personalized cancer therapy and early diagnosis. Rapid advancements in next-generation sequencing (NGS) and increased affordability have further enhanced the adoption of genomics. The integration of bioinformatics tools with omics technologies has enabled researchers and clinicians to decode complex cancer pathways, improving diagnostic accuracy and treatment decisions. The increasing availability of cancer genome databases and public-private research funding also supports the growth of this segment.

For instance, Illumina’s NovaSeq™ 6000 platform is capable of sequencing up to 6 terabases in a single run, supporting whole-genome sequencing of approximately 48 human genomes at 30x coverage, which significantly accelerates cancer biomarker discovery.

By Cancer Type

Breast cancer remains the dominant cancer type segment in the Cancer Biomarkers market, contributing the highest market share in 2024. The high incidence rate globally, coupled with well-established screening programs and early detection initiatives, supports its leading position. Biomarker-based tests, such as HER2 and BRCA1/2, play a crucial role in guiding targeted therapies and improving patient outcomes. Moreover, growing awareness, government support for early screening, and technological innovations in diagnostic imaging and molecular assays continue to drive the demand for cancer biomarkers in breast cancer detection and management.

Key Growth Drivers

Rising Prevalence of Cancer Globally
The increasing incidence of various cancers, including breast, lung, and colorectal, is a primary driver of the cancer biomarkers market. According to the WHO, cancer is a leading cause of death worldwide, with millions of new cases reported annually. This surge in cancer burden has amplified the demand for early detection and diagnostic tools, fueling the adoption of cancer biomarkers. These biomarkers assist in identifying the disease at an early stage, improving treatment outcomes, and driving the need for more personalized and targeted therapies across global healthcare systems.

For instance, Roche’s Elecsys® CEA assay is widely used for early detection and monitoring of colorectal cancer recurrence and was reported in clinical practice to detect cancer recurrence approximately 4 to 6 months before imaging methods in over 50% of cases.

Advancements in Genomics and Proteomics Technologies
Technological innovations in genomics, proteomics, and bioinformatics are significantly enhancing the capabilities of cancer biomarker discovery and validation. The integration of next-generation sequencing (NGS), mass spectrometry, and artificial intelligence enables more accurate identification and profiling of biomarkers. These innovations have paved the way for precision oncology, where therapies are tailored to the molecular characteristics of an individual’s cancer. As technology continues to evolve, it enhances the reliability and accessibility of biomarker-based diagnostics, encouraging widespread adoption in clinical and research applications.

For instance, the Clinical Proteomic Tumor Analysis Consortium (CPTAC), led by the U.S. National Cancer Institute, has generated over 13,000 proteomic profiles and integrated them with genomic data across 10 tumor types, significantly advancing biomarker discovery and translational cancer research.

Growing Demand for Personalized Medicine
The shift toward personalized medicine has led to a growing reliance on cancer biomarkers to customize treatment plans based on individual tumor biology. Biomarkers help predict patient responses to specific drugs, minimizing adverse effects and improving therapeutic efficacy. This approach is particularly important in oncology, where treatment regimens vary significantly by genetic and molecular cancer subtypes. Pharmaceutical companies are increasingly incorporating biomarker strategies in clinical trials, which is accelerating companion diagnostics development and fueling market growth across drug discovery and development pipelines.

Key Trends & Opportunities

Integration of Artificial Intelligence and Machine Learning
The incorporation of artificial intelligence (AI) and machine learning (ML) in biomarker research is transforming cancer diagnostics and prognostics. These technologies enable rapid data analysis, pattern recognition, and predictive modeling from vast genomic and clinical datasets. AI-driven algorithms improve biomarker validation, enhance diagnostic accuracy, and reduce the time required for clinical decision-making. This trend is opening new opportunities for market players to develop AI-powered biomarker platforms, creating a competitive edge through automation and precision-driven approaches.

For instance, Tempus Labs’ AI-driven Tempus TO platform has analyzed more than 5 million clinical and molecular records to support biomarker discovery and therapy selection, contributing to more than 400 active research collaborations globally.

Rising Collaborations and Strategic Partnerships
Strategic collaborations between pharmaceutical companies, diagnostic developers, and research institutions are accelerating biomarker discovery and commercialization. These partnerships foster resource sharing, co-development of novel assays, and faster regulatory approvals. Government-backed research initiatives and public-private partnerships are further encouraging biomarker innovation. For instance, national genomics initiatives in the U.S., U.K., and China have bolstered cancer biomarker pipelines. Such collaborations offer substantial growth potential, especially in developing targeted therapies and companion diagnostics aligned with regulatory and clinical guidelines.

For instance, in 2022, Illumina and AstraZeneca collaborated to combine genomics and AI to accelerate the identification of therapeutic targets, analyzing over 500,000 whole-genome sequences from AstraZeneca’s clinical trials to improve cancer biomarker development.

Key Challenges

High Cost of Biomarker Validation and Clinical Trials

The validation of cancer biomarkers involves complex, multi-phase clinical trials and rigorous regulatory scrutiny, making the process time-consuming and expensive. The financial burden of conducting large-scale studies and meeting stringent compliance standards often deters smaller companies from entering the market. Moreover, the cost of developing companion diagnostics in tandem with therapeutic agents adds to the economic strain. These high costs can limit the pace of innovation and delay the commercial availability of novel biomarkers.

Lack of Standardization and Reproducibility

A critical challenge in the cancer biomarkers market is the lack of standardization in testing procedures and biomarker assay formats. Variability in sample collection, data interpretation, and testing protocols across laboratories leads to inconsistent results and affects clinical reliability. This reproducibility issue hinders the widespread adoption of certain biomarker tests and limits their integration into routine clinical practice. Regulatory agencies are increasingly emphasizing the need for standardized methods, but harmonization remains a work in progress.

Regulatory and Ethical Complexities

Navigating the regulatory landscape for cancer biomarkers, particularly those used in companion diagnostics, is complex and evolving. Each region has distinct approval pathways and compliance requirements, which can delay market entry and increase development timelines. Additionally, ethical concerns surrounding genetic data privacy and informed consent pose challenges for biomarker research, especially in population-based genomic studies. These regulatory and ethical barriers require careful navigation to ensure successful product development and commercialization.

Regional Analysis

North America

North America held the largest share of the global cancer biomarkers market in 2024, accounting for approximately 31.7% of total revenue. The market grew from USD 4,774.67 million in 2018 to USD 7,794.06 million in 2024, and it is projected to reach USD 14,744.59 million by 2032, expanding at a CAGR of 8.3%. This growth is driven by advanced healthcare infrastructure, increasing investments in precision oncology, and rising adoption of companion diagnostics. The U.S. continues to lead in cancer research and biomarker-based clinical trials, supported by favorable reimbursement policies and active participation of major pharmaceutical companies.

Europe

Europe represented approximately 26.5% of the global cancer biomarkers market in 2024, with market size rising from USD 3,824.13 million in 2018 to USD 6,508.15 million in 2024. The market is expected to reach USD 13,026.96 million by 2032, growing at a CAGR of 9.1%. Factors fueling this growth include increased government funding for cancer diagnostics, growing adoption of personalized therapies, and expansion of genomics research across EU countries. Leading economies such as Germany, the U.K., and France are witnessing high demand for early cancer detection tools, boosting the clinical utility and commercialization of biomarkers.

Asia Pacific

Asia Pacific accounted for nearly 24.3% of the cancer biomarkers market share in 2024 and is the fastest-growing regional market with a CAGR of 9.7%. The market increased from USD 3,383.28 million in 2018 to USD 5,980.31 million in 2024, and is projected to reach USD 12,544.48 million by 2032. Rapid economic development, rising cancer prevalence, and improvements in healthcare access are driving demand. Countries such as China, India, and Japan are heavily investing in genomic medicine and diagnostic technologies, supported by growing clinical trial activity and a large patient base seeking early cancer screening solutions.

Latin America

Latin America captured around 9.6% of the global cancer biomarkers market share in 2024, expanding from USD 1,526.14 million in 2018 to USD 2,368.26 million in 2024. It is forecast to reach USD 4,149.33 million by 2032, with a CAGR of 7.3%. Growth in the region is driven by rising awareness of cancer screening, increasing healthcare expenditure, and gradual adoption of biomarker-based diagnostics. Countries such as Brazil and Mexico are showing promising potential through public-private partnerships aimed at improving cancer care infrastructure, though challenges around regulatory approvals and reimbursement persist in some parts of the region.

Middle East

The Middle East accounted for 4.8% of the cancer biomarkers market in 2024, with market value increasing from USD 683.98 million in 2018 to USD 1,182.02 million in 2024, and projected to reach USD 2,412.40 million by 2032 at a CAGR of 9.4%. The region’s growth is supported by expanding healthcare investments in countries like Saudi Arabia and the UAE, where national cancer control programs are promoting early diagnosis and advanced diagnostics. A growing focus on research collaborations and biomarker-based treatment frameworks is encouraging the adoption of personalized medicine across major urban centers.

Africa

Africa represented approximately 3% of the global market share in 2024, with the market growing from USD 454.03 million in 2018 to USD 734.20 million in 2024, and anticipated to reach USD 1,370.24 million by 2032 at a CAGR of 8.1%. Although the market size remains modest, increasing cancer burden, international donor support, and growing adoption of diagnostic tools are boosting growth. Several countries are investing in national cancer registries and awareness campaigns. However, limited access to advanced healthcare services and underdeveloped infrastructure continue to pose challenges to widespread implementation of biomarker-based screening and treatment.

Market Segmentations:

By Product

Instruments
Consumables
- Antibodies
- Kits & Reagents
- Probes

By Profiling Technologies

Omics Technologies
- Proteomics
- Genomics
Imaging Technologies
Bioinformatics
Others

By Cancer Type

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Others

By Application

Pharmaceutical and Biotechnology Companies
Diagnostics
Drug Discovery & Development
Prognostics
Risk Assessment
Others

By Geography

North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Competitive Landscape

The Cancer Biomarkers market is highly competitive, with key players focusing on innovation, strategic partnerships, and geographic expansion to strengthen their market position. Leading companies such as Qiagen N.V., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., and Illumina, Inc. dominate the landscape with extensive product portfolios and strong R&D capabilities. These firms actively invest in next-generation sequencing, liquid biopsy platforms, and companion diagnostics to enhance early cancer detection and personalized treatment options. Collaborations between pharmaceutical and diagnostic companies have become increasingly common, particularly for co-developing biomarker-based targeted therapies. Mergers and acquisitions are also prevalent as companies seek to expand their technological capabilities and access emerging markets. Meanwhile, rising competition from regional players and emerging biotech firms continues to reshape the market dynamics, prompting global companies to maintain product differentiation and regulatory compliance. Overall, the competitive environment remains dynamic, driven by technological advancement, clinical demand, and evolving healthcare frameworks.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Qiagen N.V.
Hoffmann-La Roche Ltd
Illumina, Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific Inc.
Sino Biological Inc.

Recent Developments

In May 2025, Agilent Technologies announced a strategic partnership with Ubix Therapeutics to develop targeted protein degradation (TPD) and antibody-drug conjugate (ADC) therapies, leveraging Agilent’s analytical technologies for cancer biomarker research.
In May 2025, Thermo Fisher Scientific Inc. showcased new data on precision oncology at ASCO 2025, highlighting NGS technologies for biomarker discovery and companion diagnostics. Supported over 750 hematology and oncology clinical trials globally in the past five years.
In April 2025, Agilent Technologies announced several advancements in cancer research with the introduction of Avida DNA Cancer Panels, a new solution for simultaneous DNA and methylation profiling from a single sample, alongside an expansion of the SureSelect Cancer CGP Assay through a partnership with Tagomics to offer multiomic insights. They also launched the SureSelect Cancer Pan Heme Assay, developed in collaboration with Roswell Park Comprehensive Cancer Center, specifically designed for hematologic malignancies.
In November 2024, Bio-Rad Laboratories announced two significant advancements: achieving IVDR Class C certification for their QXDx BCR-ABL %IS Kit, which uses Droplet Digital PCR (ddPCR) to monitor chronic myeloid leukemia (CML), and launching over 50 new ddPCR Methylation Detection Assays for early cancer detection and monitoring.
In 2024, Bio-rad laboratories, inc. collaborated with Allegheny Health Network and Aarhus University Hospital on MRD monitoring in solid tumors and colorectal cancer using ddPCR. Also partnered with Biodesix and Memorial Sloan Kettering Cancer Center to develop multiplexed ddPCR oncology assays for lung cancer.

Market Concentration & Characteristics

The Cancer Biomarkers Market exhibits a moderate to high level of market concentration, with a few dominant players such as Roche, Thermo Fisher Scientific, Qiagen, and Illumina holding significant global shares. It is characterized by rapid technological advancement, a strong emphasis on precision medicine, and a growing integration of genomic and proteomic platforms in clinical diagnostics. The market prioritizes early detection, non-invasive testing methods, and personalized treatment strategies, which drive the adoption of biomarker-based solutions across healthcare systems. It maintains a dynamic structure, with continuous innovation, strategic collaborations, and regulatory shifts influencing competitive positioning. Leading companies invest heavily in research and development while forming alliances with pharmaceutical firms to co-develop companion diagnostics. Emerging players contribute to innovation but face high entry barriers due to stringent validation protocols, complex regulatory environments, and the need for robust clinical data. It responds swiftly to trends in cancer incidence, diagnostic accuracy, and payer demand for cost-effective testing. The presence of diverse technologies and varied clinical applications supports steady growth, while regional differences in infrastructure and reimbursement policies create segmentation across geographies.

Report Coverage

The research report offers an in-depth analysis based on Product, Profiling Technologies, Cancer Type, Application and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The cancer biomarkers market will continue to grow steadily due to increasing global cancer incidence.
Demand for non-invasive and early detection tools will drive adoption of biomarker-based diagnostics.
Precision medicine will remain a key focus, boosting the use of biomarkers in personalized treatment planning.
Integration of AI and machine learning will enhance biomarker discovery and clinical decision-making.
Companion diagnostics will gain traction as pharmaceutical firms align therapies with specific biomarkers.
Omics technologies, particularly genomics and proteomics, will dominate future biomarker profiling strategies.
Strategic partnerships between diagnostic and pharmaceutical companies will accelerate innovation and commercialization.
Emerging economies will offer significant growth opportunities due to rising healthcare access and awareness.
Regulatory harmonization efforts will improve approval timelines for new biomarker-based tests.
Continued investment in research and development will drive the expansion of biomarker applications across cancer types.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : CANCER BIOMARKERS MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Technologies Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Product, Profiling Technologies, Cancer Type, & Application Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis By Region

6.1.1. Global Cancer Biomarkers Market Import Revenue By Region

6.2. Export Analysis By Region

6.2.1. Global Cancer Biomarkers Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Cancer Biomarkers Market: Company Market Share

7.2. Global Cancer Biomarkers Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : CANCER BIOMARKERS MARKET – BY PRODUCT SEGMENT ANALYSIS

8.1. Cancer Biomarkers Market Overview By Product Segment

8.1.1. Cancer Biomarkers Market Revenue Share By Product

8.2. Instruments

8.3. Consumables

8.3.1. Antibodies

8.3.2. Kits & Reagents

8.3.3. Probes

CHAPTER NO. 9 : CANCER BIOMARKERS MARKET – BY PROFILING TECHNOLOGIES SEGMENT ANALYSIS

9.1. Cancer Biomarkers Market Overview By Profiling Technologies Segment

9.1.1. Cancer Biomarkers Market Revenue Share By Profiling Technologies

9.2. Omics Technologies

9.2.1. Proteomics

9.2.2. Genomics

9.3. Imaging Technologies

9.4. Bioinformatics

9.5. Others

CHAPTER NO. 10 : CANCER BIOMARKERS MARKET – BY CANCER TYPE SEGMENT ANALYSIS

10.1. Cancer Biomarkers Market Overview By Cancer Type Segment

10.1.1. Cancer Biomarkers Market Revenue Share By Cancer Type

10.2. Breast Cancer

10.3. Lung Cancer

10.4. Colorectal Cancer

10.5. Prostate Cancer

10.6. Cervical Cancer

10.7. Others

CHAPTER NO. 11 : CANCER BIOMARKERS MARKET – BY APPLICATION SEGMENT ANALYSIS

11.1. Cancer Biomarkers Market Overview By Application Segment

11.1.1. Cancer Biomarkers Market Revenue Share By Application

11.2. Pharmaceutical and Biotechnology Companies

11.3. Diagnostics

11.4. Drug Discovery & Development

11.5. Prognostics

11.6. Risk Assessment

11.7. Others

CHAPTER NO. 12 : CANCER BIOMARKERS MARKET – REGIONAL ANALYSIS

12.1. Cancer Biomarkers Market Overview By Region Segment

12.1.1. Global Cancer Biomarkers Market Revenue Share By Region

12.1.2. Regions

12.1.3. Global Cancer Biomarkers Market Revenue By Region

12.1.4. Product

12.1.5. Global Cancer Biomarkers Market Revenue By Product

12.1.6. Type

12.1.7. Global Cancer Biomarkers Market Revenue By Type

12.1.8. Cancer Type

12.1.9. Global Cancer Biomarkers Market Revenue By Cancer Type

12.1.10. Application

12.1.11. Global Cancer Biomarkers Market Revenue By Application

CHAPTER NO. 13 : NORTH AMERICA CANCER BIOMARKERS MARKET – COUNTRY ANALYSIS

13.1. North America Cancer Biomarkers Market Overview By Country Segment

13.1.1. North America Cancer Biomarkers Market Revenue Share By Region

13.2. North America

13.2.1. North America Cancer Biomarkers Market Revenue By Country

13.2.2. Product

13.2.3. North America Cancer Biomarkers Market Revenue By Product

13.2.4. Profiling Technologies

13.2.5. North America Cancer Biomarkers Market Revenue By Profiling Technologies

13.2.6. Cancer Type

13.2.7. North America Cancer Biomarkers Market Revenue By Cancer Type

13.2.8. Application

13.2.9. North America Cancer Biomarkers Market Revenue By Application

13.3. U.S.

13.4. Canada

13.5. Mexico

CHAPTER NO. 14 : EUROPE CANCER BIOMARKERS MARKET – COUNTRY ANALYSIS

14.1. Europe Cancer Biomarkers Market Overview By Country Segment

14.1.1. Europe Cancer Biomarkers Market Revenue Share By Region

14.2. Europe

14.2.1. Europe Cancer Biomarkers Market Revenue By Country

14.2.2. Product

14.2.3. Europe Cancer Biomarkers Market Revenue By Product

14.2.4. Profiling Technologies

14.2.5. Europe Cancer Biomarkers Market Revenue By Profiling Technologies

14.2.6. Cancer Type

14.2.7. Europe Cancer Biomarkers Market Revenue By Cancer Type

14.2.8. Application

14.2.9. Europe Cancer Biomarkers Market Revenue By Application

14.3. UK

14.4. France

14.5. Germany

14.6. Italy

14.7. Spain

14.8. Russia

14.9. Rest of Europe

CHAPTER NO. 15 : ASIA PACIFIC CANCER BIOMARKERS MARKET – COUNTRY ANALYSIS

15.1. Asia Pacific Cancer Biomarkers Market Overview By Country Segment

15.1.1. Asia Pacific Cancer Biomarkers Market Revenue Share By Region

15.2. Asia Pacific

15.2.1. Asia Pacific Cancer Biomarkers Market Revenue By Country

15.2.2. Product

15.2.3. Asia Pacific Cancer Biomarkers Market Revenue By Product

15.2.4. Profiling Technologies

15.2.5. Asia Pacific Cancer Biomarkers Market Revenue By Profiling Technologies

15.2.6. Cancer Type

15.2.7. Asia Pacific Cancer Biomarkers Market Revenue By Cancer Type

15.2.8. Application

15.2.9. Asia Pacific Cancer Biomarkers Market Revenue By Application

15.3. China

15.4. Japan

15.5. South Korea

15.6. India

15.7. Australia

15.8. Southeast Asia

15.9. Rest of Asia Pacific

CHAPTER NO. 16 : LATIN AMERICA CANCER BIOMARKERS MARKET – COUNTRY ANALYSIS

16.1. Latin America Cancer Biomarkers Market Overview By Country Segment

16.1.1. Latin America Cancer Biomarkers Market Revenue Share By Region

16.2. Latin America

16.2.1. Latin America Cancer Biomarkers Market Revenue By Country

16.2.2. Product

16.2.3. Latin America Cancer Biomarkers Market Revenue By Product

16.2.4. Profiling Technologies

16.2.5. Latin America Cancer Biomarkers Market Revenue By Profiling Technologies

16.2.6. Cancer Type

16.2.7. Latin America Cancer Biomarkers Market Revenue By Cancer Type

16.2.8. Application

16.2.9. Latin America Cancer Biomarkers Market Revenue By Application

16.3. Brazil

16.4. Argentina

16.5. Rest of Latin America

CHAPTER NO. 17 : MIDDLE EAST CANCER BIOMARKERS MARKET – COUNTRY ANALYSIS

17.1. Middle East Cancer Biomarkers Market Overview By Country Segment

17.1.1. Middle East Cancer Biomarkers Market Revenue Share By Region

17.2. Middle East

17.2.1. Middle East Cancer Biomarkers Market Revenue By Country

17.2.2. Product

17.2.3. Middle East Cancer Biomarkers Market Revenue By Product

17.2.4. Profiling Technologies

17.2.5. Middle East Cancer Biomarkers Market Revenue By Profiling Technologies

17.2.6. Cancer Type

17.2.7. Middle East Cancer Biomarkers Market Revenue By Cancer Type

17.2.8. Application

17.2.9. Middle East Cancer Biomarkers Market Revenue By Application

17.3. GCC Countries

17.4. Israel

17.5. Turkey

17.6. Rest of Middle East

CHAPTER NO. 18 : AFRICA CANCER BIOMARKERS MARKET – COUNTRY ANALYSIS

18.1. Africa Cancer Biomarkers Market Overview By Country Segment

18.1.1. Africa Cancer Biomarkers Market Revenue Share By Region

18.2. Africa

18.2.1. Africa Cancer Biomarkers Market Revenue By Country

18.2.2. Product

18.2.3. Africa Cancer Biomarkers Market Revenue By Product

18.2.4. Profiling Technologies

18.2.5. Africa Cancer Biomarkers Market Revenue By Profiling Technologies

18.2.6. Cancer Type

18.2.7. Africa Cancer Biomarkers Market Revenue By Cancer Type

18.2.8. Application

18.2.9. Africa Cancer Biomarkers Market Revenue By Application

18.3. South Africa

18.4. Egypt

18.5. Rest of Africa

CHAPTER NO. 19 : COMPANY PROFILES

19.1. Qiagen N.V.

19.1.1. Company Overview

19.1.2. Product Portfolio

19.1.3. Financial Overview

19.1.4. Recent Developments

19.1.5. Growth Strategy

19.1.6. SWOT Analysis

19.2. F. Hoffmann-La Roche Ltd

19.3. Illumina, Inc.

19.4. Agilent Technologies, Inc.

19.5. Bio-Rad Laboratories, Inc.

19.6. Thermo Fisher Scientific Inc.

19.7. Sino Biological Inc.

19.8. Other Key Players

Request Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions

What is the current size of the Cancer Biomarkers Market?

The Cancer Biomarkers Market is valued at USD 24,567.0 million in 2024 and is projected to reach USD 48,248.0 million by 2032.

What factors are driving the growth of the Cancer Biomarkers Market?

Key drivers include the rising global cancer prevalence, advancements in genomics and proteomics, and growing demand for personalized medicine.

What are the key segments within the Cancer Biomarkers Market?

The market is segmented by Product, Profiling Technologies, Cancer Type, Application, and Geography.

What are some challenges faced by the Cancer Biomarkers Market?

Challenges include high costs of biomarker validation, lack of standardization, and complex regulatory environments.

Who are the major players in the Cancer Biomarkers Market?

Leading players include Qiagen N.V., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Illumina, Inc., and Agilent Technologies.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports By Keyword

Endometrial Cancer Treatment Market

The Endometrial Cancer Treatment Market size was valued at USD 30,681.7 million in 2024 and is anticipated to reach USD 48,901.9 million by 2032, growing at a compound annual growth rate (CAGR) of 6% during the forecast period.

Colorectal Cancer Diagnostics Market

Colorectal Cancer Diagnostics Market size was valued at USD 14502.5 million in 2024 and is anticipated to reach USD 23465 million by 2032, at a CAGR of 6.2% during the forecast period.

At-Home Cancer Testing Market

The At-Home Cancer Testing Market size was valued at USD 6,037.48 million in 2018, reached USD 8,047.53 million in 2024, and is anticipated to reach USD 11,576.07 million by 2032, growing at a CAGR of 4.33% during the forecast period.

Kidney Cancer/Renal Cell Carcinoma Drugs Market

The Renal Cell Carcinoma (RCC) Drugs Market size was valued at USD 3,873.8 million in 2018, increased to USD 5,776.4 million in 2024, and is anticipated to reach USD 9,313.8 million by 2032, at a CAGR of 6.13% during the forecast period.

Mobile Cancer Screening Devices Market

The Mobile Cancer Screening Devices Market size was valued at USD 2,750.00 million in 2018 to USD 3,576.07 million in 2024 and is anticipated to reach USD 6,973.11 million by 2032, at a CAGR of 8.78 % during the forecast period.

Blood Cancer Treatment Market

The blood cancer treatment market is projected to grow from USD 39,790 million in 2024 to USD 64,140.7 million by 2032, registering a CAGR of 6.15% during the forecast period.

Cervical Cancer Treatment Market

The Cervical Cancer Treatment market size was valued at USD 7,350.00 million in 2018, reached USD 8,241.48 million in 2024, and is anticipated to reach USD 12,217.54 million by 2032, at a CAGR of 5.10% during the forecast period.

Colorectal Cancer Therapeutics Market

The Colorectal Cancer Therapeutics Market is projected to grow from USD 12,945.6 million in 2024 to USD 18,269.47 million by 2032, registering a CAGR of 4.4% during the forecast period.

Multi-Cancer Early Detection (MCED) Market

The Multi-Cancer Early Detection (MCED) market is projected to grow from USD 1,870 million in 2024 to USD 6,656.75 million by 2032, with a compound annual growth rate (CAGR) of 17.2%.

Purchase Options

Single User

$4999

Multi User

$6999

Enterprise

$12999

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Report delivery within 24 to 48 hours

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample